On June 17, 2025 Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and Nusano, a physics company enabling breakthrough radioisotope supplies, reported a long-term supply agreement designed to support the Ratio’s product pipeline and enable innovation (Press release, Nusano, JUN 17, 2025, View Source [SID1234653951]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement gives Ratio access to reliable, high-volume, commercial-scale supplies of copper-64 (Cu-64) for PET imaging diagnostics produced by Nusano, as well as lutetium-177 (Lu-177) and actinium-225 (Ac-225) for therapeutic applications.
"We are pleased to enter into this agreement with Nusano, a company whose isotope production platform enables Ratio to secure a critical supply chain advantage. By gaining access to Cu-64 for imaging and Ac-225 for therapies, we can confidently advance our radiopharmaceutical clinical programs," said Jack Hoppin, Ph.D., Chairman and Chief Executive Officer of Ratio Therapeutics. "Limited supply and high costs of Cu-64 have put significant constraints on its clinical use. By accessing Nusano’s production capabilities, we’re removing a critical bottleneck and enabling broader adoption across the field. This agreement de-risks our development pipeline and positions us to deliver innovative radiopharmaceuticals to patients across the U.S. and beyond."
Nusano is a radioisotope producer with a proprietary platform capable of generating more than 40 different isotopes for medical and industrial applications. The company intends to use these capabilities to help stabilize the existing medical radioisotope market and enable oncology innovation by providing researchers and drugmakers with isotopes yet to be fully explored for their cancer-fighting properties.
"This agreement is the foundation for a strategic alliance aimed at unlocking the full potential of radiopharmaceuticals," said Chris Lowe, Chief Executive Officer of Nusano. "We’re seeing strong, sustained growth in the use of Cu-64 for PET imaging and rapidly increasing interest in isotopes such as Ac-225 for targeted cancer treatments. By collaborating with forward-thinking radiopharmaceutical companies like Ratio, we’re working to meet current clinical needs and support the development of next-generation radiopharmaceuticals."
This supply agreement reflects the shared vision of the two companies to accelerate innovation in the radiopharmaceutical field as the demand for diagnostic and therapeutic isotopes continues to grow. The close proximity of Ratio’s new manufacturing facility in Utah, just miles from Nusano’s operations, will streamline the logistics involved in scale-up and delivery. Supplies of Lu-177 and Ac-225 from Nusano will also play an important role in Ratio’s growing radiopharmaceutical pipeline. Leveraging its proprietary Trillium platform, Ratio is designing highly selective, targeted radiotherapeutics for cancer treatment, including a FAP-targeted radiotherapy in development for soft tissue sarcoma which is expected to enter the clinic this year.